GLP-1 receptor agonist on cardiovascular complications of diabetes mellitus
| Autor: | Fengjun Liu, Yanhua Kong |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Agonist Cancer Research medicine.medical_specialty medicine.drug_class Disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Immunology and Microbiology (miscellaneous) Internal medicine Diabetes mellitus medicine Clinical efficacy Glucagon-like peptide 1 receptor business.industry Cancer General Medicine Articles medicine.disease Molecular medicine 030104 developmental biology 030220 oncology & carcinogenesis business Glipizide medicine.drug |
| Zdroj: | Experimental and therapeutic medicine. 19(3) |
| ISSN: | 1792-0981 |
| Popis: | Effects of glucagon-like peptide-1 (GLP-1) receptor agonist on cardiovascular complications of diabetes mellitus (DM) were investigated. In total, 132 DM patients treated in Tengzhou Central People's Hospital from April 2013 to September 2016 were included. Of these, 71 cases treated with basic drugs plus GLP-1 were the research group, and 61 cases treated with glipizide controlled release tablets the control group. The improvement of clinical efficacy of patients in the two groups after treatment was observed. The concentrations of FPG, HbAlc, TC, LDL-C, and HDL-C in serum of patients in the two groups before and after treatment were compared, and the incidence rate of cardiovascular disease complications of diabetes was recorded. Expression of FPG, HbAlc, TC, LDL-C, and HDL-C of patients in the two groups were further detected. ROC curve was drawn to analyze its predictive value. In terms of markedly effective treatment rate and overall effective rate, the research group was significantly better than the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|